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Abstract
Purpose: To investigate second cancer risk (SCR) comparing volumetric modulated arc therapy (VMAT) and 3D
conformal radiotherapy (3DCRT) with different high dose fractionation schemes.
Methods: VMAT and 3DCRT virtual treatment plans for 25 patients previously treated with radiotherapy for rectal
cancer were evaluated retrospectively. Doses prescribed were 25 × 1.8 Gy and 5 × 5 Gy, respectively. SCR was
estimated using a carcinogenesis model and epidemiological data for carcinoma and sarcoma induction. SCR was
determined by lifetime attributable risk (LAR).
Results: Mean excess LAR was highest for organs adjacent to the PTV. Total LAR for VMAT and 3DCRT was 2.3–3.0
and 2.0–2.7 %, respectively. For 5 × 5 Gy, LAR was 1.4–1.9 % for VMAT and 1.2–1.6 % for 3DCRT. Organ-specific
excess LAR was significantly higher for VMAT, and highest for bladder and colon. Size and shape of the PTV
influenced SCR and was highest for age ≤ 40 years. For a patient with an additional lifetime risk of 60 years, LAR
was 10 % for 25 × 1.8 Gy and 6 % for 5 × 5 Gy.
Conclusions: No statistically significant difference was detected in SCR using VMAT or 3DCRT. For bladder and
colon, organ-specific excess LAR was statistically lower using 3DCRT, however the difference was small. Compared
to epidemiological data, SCR was smaller when using a hypofractionated schedule. SCR was 2 % higher at normal
life expectancy.
Trial registration: ClinicalTrials.gov Identifier NCT02572362. Registered 4 October 2015. Retrospectively registered.
Keywords: Second malignancies, Rectal cancer, Radiotherapy, Intensity-modulated radiotherapy,
Volumetric-modulated arc therapy
Introduction
Second cancer risk (SCR) is of concern in long-term
radiotherapy (RT) survivors [1]. In their analysis using
actuarial life-table procedures from the Uppsala Trial [2]
and the Swedish Rectal Cancer Trial [3] Birgission et al.
found an increased SCR in patients with rectal cancer
treated with 3D conformal radiotherapy (3DCRT) in
organs adjacent to the irradiated volume (RR 2.04; 95 %
CI, 0.97–3.27) [4]. Wiltink et al. could not confirm an
elevated SCR in a more recent series contributing to an
increasingly controversial discussion [5]. Kendal and
Nicholas showed in their population-based analysis from
the Surveillance, Epidemiology, and End Results registry
(SEER) that second cancers after RT appeared infre-
quently compared with background incidence of spon-
taneous cancers. As the median age of patients with
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rectal cancer is 68 years, they concluded that SCR might
not be as significant compared to the therapeutic benefit
and should not factor into treatment decisions for this
older population [6]. However, reduction of SCR is rele-
vant as local control increased with standard treatment in-
cluding preoperative chemoradiotherapy followed by total
mesorectal excision (TME) for stage II and III rectal can-
cer [7]. Studies have also investigated the use of a shorter
course of preoperative RT (25 Gy over 5 days) without
chemotherapy. It appears that short course RT results in
isoeffective local control and OS compared to a long
course chemoradiotherapy schedule (45 Gy over 25 days)
[8]. Long term follow up of the Dutch TME trial compar-
ing short course RT with no RT demonstrated that second
malignancies were more frequent in the RT group (14 %
vs. 9 %) [9]. Chemotherapy is another co-factor contribut-
ing to an increase in SCR in the population of cancer sur-
vivors. Long known to be leukemogenic, chemotherapy
appears also to contribute to risk for a range of other sec-
ond malignancies [10].
Recording epidemiological data on second cancers
after RT for rectal cancer necessitates observation of a
large group of patients over several decades. SCR is rea-
sonably well quantified from atomic bomb survivors at
moderately low doses of radiation up to 2 Gy. However,
there is much more uncertainty at higher doses used in
therapeutic RT [11]. We performed a model-based
analysis calculating the organ-specific excess lifetime
attributable risk (LAR) [12–14] to estimate SCR for
patients after radiotherapy for rectal cancer comparing
3DCRT with VMAT technique.
Methods and materials
Planning CT data of 25 patients with stage I – III rectal
cancer treated with pre- or postoperative RT in 2011 to
2013 were reused for comparative treatment planning
(Table 1). Patients gave informed consent to this ethic-
ally approved retrospective study (ClinicalTrials.gov
Identifier: NCT02572362).
Volume segmentation
Clinical target volumes (CTV) were delineated corre-
sponding to the radiation therapy oncology group
(RTOG) consensus panel contouring atlas [15]. Organs
of interest with respect to cancer induction were
contoured on each CT data set according to the
International Commission on Radiological Protection
(ICRP) 2007 [16].
Treatment planning
For the planning target volume (PTV), an isotropic
5 mm margin was added to the CTV. 3DCRT consisted
of a three-field technique - the 6 MV photon beam
energy for the posteroanterior fields and 15 MV for the
lateral fields were used. For five patients, 15 MV beams
were applied in all three fields for anatomical reasons.
Dynamic wedges were used to optimize dose distribu-
tion. For VMAT plans, photon beam energy was 6 MV
using a dynamic multileaf collimator technique and one
rotation per fraction. Dose rates were up 600 MU/min
at maximum for both techniques. Doses prescribed were
45.0 Gy in 1.8 Gy and 25 Gy in 5 Gy per fraction,
respectively. Treatment plans were normalised such that
the 95 %-isodose was encompassing 98 % of the PTV
volume. Eclipse External Beam Planning system version
10.0 (Varian Oncology Systems, Palo Alto, CA) and the
AAA-algorithm (version 10.0.28) was used for treatment
planning. Differential dose volume histograms (DVH)
were generated for each plan.
Estimation of second cancer risk
The carcinogenesis model used to estimate SCR empha-
sizes cell kinetics of radiation-induced cancer by muta-
tional processes and is reported in detail elsewhere [14,
17, 18]. Briefly, the model describes carcinoma and sar-
coma induction after fractionated RT as an analytical
function and integrates cell sterilization processes
described by the linear-quadratic model and repopula-
tion effects. The linear-quadratic model of cell kill is
applied to normal tissues that are irradiated during RT.
Table 1 Study population characteristics (N = 25)
Age Years
-Mean, SD 64.8 ± 8.2
-Median (min/max) 64 (46–83)














Monitor units (MU) Mean, SD
−3DCRT 269.5 ± 15.1
-VMAT 512.7 ± 40.1
SD standard deviation, AJCC American Joint Committee on Cancer, RT
Radiotherapy, VMAT volumetric modulated arc therapy, 3DCRT 3 dimensional
conformal radiotherapy
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Tumor induction is modelled such that each transform-
ation process results in a tumor cell. Cancer induction
in this model is a function of treatment dose, dose per
fraction, defined cell kill parameters, tumor induction
variable and repopulation parameter [17]. The obtained
dose-response relationship for carcinoma and sarcoma
induction can be used in models for predicting
radiation-induced cancer after RT such as the organ-
equivalent dose (OED) model [14]. The model parame-
ters used in this work were obtained by fits to several
epidemiological, cancer specific carcinogenesis data for
carcinoma and sarcoma induction. Radiation induced
cancer estimates were determined with the obtained
model parameters from the publication by Schneider et
al. [13]. Soft tissue sarcoma induction was estimated on
the basis of the DVH for all normal tissues without the
segmented organs and bone. For bone sarcoma induc-
tion, the DVH of the complete bone structure was used.
The sarcoma-induction model is based on qualitative
observations, like the vanishing sarcoma risk at low dose
(A-bomb survivors) and the larger risk at high dose
levels (RT patients) [13, 19]. The quality of epidemio-
logical data is not strong enough to determine all model
parameters. Therefore, sarcoma risk is given for three
different regeneration/repopulation rates: R = 0.1, 0.5
and 1 which represent no, intermediate and full
repopulation.
From the DVHs of structures of interest, cancer risk
was estimated in terms of organ equivalent dose (OED)
[14]. OED is proportional to cancer risk and was con-
verted to excess absolute risk for a western population
for each organ as well as for all organs together [17].
Lifetime cancer risk for a patient was determined by
LAR according to Kellerer et al. [12] by an integration of
excess absolute risk from the age at exposure to the
lifetime expectancy. LAR is a lifetime risk and not
applicable to epidemiological studies which include
subjects with limited follow-up time. Therefore, cumula-
tive risk is determined for these patients by taking into
account the follow-up time of Birgisson et al. [4] instead
of the life expectancy.
The epidemiological data are usually given in absolute
risk, the modelled risk however in excess absolute risk.
Therefore, the model of the base line risks was fitted to
the epidemiological obtained SCR data of Birgisson et al.
[4]. The sum of modelled base line risk and excess
absolute risk can then be compared to the epidemio-
logical risk found by Birgisson et al. [4].
Statistical analysis
For every treatment plan differential DVHs were
exported from the treatment planning software Eclipse
External Beam Planning system version 10.0 (Varian
Oncology Systems, Palo Alto, CA). Monitor units (MU),
total dose and dose prescribed per fraction; PTV size
and volumes of the organs of interest, age at exposure
and gender were recorded. Statistical analysis was
performed with R, version 3.0.2 (2013-09-25), (R
Foundation for Statistical Computing, Vienna, Austria).
Median, mean values and standard deviation of the
mean (SD) were collected. Student’s T-test for paired
samples and nonparametric Wilcoxon signed-rank test
were used. A p value < 0.05 was considered statistically
significant. Confidence intervals (CI) included 95 % of
the measured data.
Results
Mean percentage excess LAR for segmented organs,
bones or soft tissues as well as sex specific LAR are
shown in Table 2. Analysis was performed using actual
age of patients at the time of RT. LAR was integrated up
to an attained age of 90 years.
Mean excess LAR was highest for organs adjacent or
close to the PTV (Table 2). For all organs using 25 ×
1.8 Gy, the LAR for VMAT and 3DCRT was 2.3 – 3.0 and
2.0 – 2.7 %, respectively (Table 2). For 5 × 5 Gy, LAR was
Table 2 Excess lifetime attributable risk (LAR) after RT
Organa Mean LAR VMAT (%) Mean LAR 3DCRT (%)
25 × 1.8 Gy 5 × 5 Gy 25 × 1.8 Gy 5 × 5 Gy
Anus 0.3330 0.1973 0.3098 0.1835
Bladder 0.2151 0.2260 0.1067 0.1144
Bones R = 1 0.1734 0.0881 0.1756 0.0864
Bones R = 0.5 0.0591 0.0273 0.0573 0.0257
Bones R = 0.1 0.0031 0.0013 0.0029 0.0013
Colon 1.0225 0.5677 0.8554 0.4754
Sigmoid 0.4732 0.2882 0.4981 0.3020
Skin 0.0519 0.0288 0.0461 0.0256
Small bowel 0.1328 0.1088 0.1240 0.0977
Soft tissue R = 1 0.1007 0.0474 0.0768 0.0357
Soft tissue R = 0.5 0.0344 0.0153 0.0254 0.0115
Soft tissue R = 0.1 0.0024 0.0011 0.0019 0.0008
Prostate 0.0354 0.0242 0.0346 0.0236
Ovaries 0.2756 0.1944 0.2838 0.2053
Uterus 0.1997 0.1383 0.1826 0.1220
All organs male R = 1 2.5380 1.5764 2.2270 1.3443
All organs male R = 0.5 2.3574 1.4835 2.0573 1.2593
All organs male R = 0.1 2.2694 1.4433 1.9795 1.2242
All organs female R = 1 2.9778 1.8849 2.6589 1.6480
All organs female R = 0.5 2.7972 1.7920 2.4892 1.5630
All organs female R = 0.1 2.7093 1.7518 2.4113 1.5279
VMAT volumetric modulated arc therapy, 3DCRT 3 dimensional conformal
radiotherapy, R regeneration rate for soft tissue and bones, with possible
sarcoma induction
afemale/male data mixed if not otherwise indicated
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1.4 – 1.9 % for VMATand 1.2 – 1.6 % for 3DCRT and half
as high as for the long course RT scheme (Table 2). Com-
paring VMAT with 3DCRT, median percentage excess
LAR difference for bladder, colon, anus, small bowel, soft
tissue and skin was significantly higher for VMAT
irrespective of fractionation (Table 3). Percentage excess
LAR difference was highest for bladder and colon. Excess
LAR for sarcomas was small compared to carcinoma inde-
pendent of which repopulation rate was used.
Large patient specific differences in excess LAR could
be determined for 25 × 1.8 Gy, ranging from 15.9 % for
patients younger than 50 years and 0.2 % for patients
older than 80 years. Accordingly, when using the 5 ×
5 Gy regimen excess LAR was 9.6 % for patients under
50 years and 0.1 % for those over 80 years (Figs. 1 and 2)
and regeneration/repopulation rates (R = 0.1, 0.5, 1) did
not influence excess LAR. Percentage excess LAR was
higher for VMAT for patients younger than 60 years.
However, mean excess LAR was only 2 % for the long
course RT and 1.5 % for the short course regimen using
either technique. Therefore, SCR could not only be
explained by age at exposure, but also by other factors
including size and shape of the target volume.
Figures 3 and 4 show excess LAR for patients at differ-
ent ages of exposure and attained age of 90 years. SCR
was highest for patients younger than 40 years of age.
According to our model, a 30-year-old irradiated patient
with an additional lifetime of 60 years, has an excess
LAR of 10 % for 25 × 1.8 Gy and 6 % for 5 × 5 Gy. LAR
difference decreased with age between the long and
short course schedules. For patients 65 – 70 years of age
and an age most commonly diagnosed and treated for
rectal cancer, calculated second cancer risk difference
was 0.3 % and statistically non-significant, irrespective of
RT regimen and technique used.
To estimate accuracy of the S-model [17] used in this
work, we compared our results with epidemiological
data reported by Birgisson et al. [4]. LAR calculations
were performed for an age at RT exposure of 69 years
(corresponding to median age at diagnosis of rectal
cancer in the study of Birgisson et al. [4]), and integrated
Table 3 Excess lifetime attributable risk (LAR) VMAT vs 3DCRT
Organa 25 × 1.8 Gy (VMAT > LAR) 5 × 5 Gy (VMAT > LAR)
Median (%) 95 % CI p-value Median (%) 95 % CI p-value
Anus 0.0145 0.0016–0.0406 0.016 0.0088 0.0013–0.0241 0.013
Bladder 0.0934 0.0486–0.1491 <0.001 0.0988 0.0568–0.1572 <0.001
Bones R = 1 0.0066 −0.0223–0.0171 0.458 0.0057 −0.0089–0.0114 0.312
Bones R = 0.5 0.0040 −0.0057–0.0080 0.287 0.0026 −0.0019–0.0046 0.220
Bones R = 0.1 0.0003 −0.0002–0.0006 0.202 0.0001 −0.0001–0.0003 0.182
Colon 0.0768 0.0097–0.2674 0.015 0.0417 0.0051–0.1474 0.012
Sigmoid 0.0054 −0.0077–0.0152 0.367 0.0040 −0.0036–0.0106 0.241
Skin 0.0050 0.0027–0.0073 <0.001 0.0028 0.0014–0.0040 <0.001
Small bowel 0.0064 0.0137–0.0259 <0.001 0.0094 0.0052–0.0147 <0.001
Soft tissue R = 1 0.0195 0.0137–0.0259 <0.001 0.0094 0.0021–0.0042 <0.001
Soft tissue R = 0.5 0.0072 0.0050–0.0097 <0.001 0.0031 0.0050–0.0097 <0.001
Soft tissue R = 0.1 0.0005 0.0003–0.0006 <0.001 0.0002 0.0001–0.0003 <0.001
Prostate 0.0002 −0.0026–0.0043 0.787 0.0001 −0.0024–0.0034 0.893
Uterus 0.0089 0.0055–0.0555 0.063 0.0077 0.0042–0.0546 0.063
VMAT volumetric modulated arc therapy, 3DCRT 3 dimensional conformal radiotherapy, R regeneration rate for soft tissue and bones, with possible sarcoma
induction, CI confidence interval
afemale/male data mixed if not otherwise indicated
Fig. 1 LAR for each patient with RT 25 × 1.8 Gy, R = 1
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up to an attained age of 89 years (Fig. 5). SCR for rectal
cancer patients was modelled using the background rate
in the patient cohort analysed by Birgisson et al. [4].
Modelled baseline risk was added to the calculated ex-
cess LAR of patients treated with 3DCRT and 28
×1.8 Gy and 5 × 5 Gy (Figs. 1 and 2), respectively. Base-
line LAR was 1.7 % after 20 years of follow-up. The
modelled excess LAR for a 2 Gy and 5 Gy fractionation
schedule was 7 and 43 % of the baseline-LAR, respect-
ively. Gradients of the attained age increasing risks were
similar for both the S-model [17] and the epidemio-
logical data. Absolute LAR at 20 years of follow-up was
compared. For the Uppsala Trial [20] (30 × 2 Gy) abso-
lute LAR was 1.8 % compared to 2.9 % for the S-model
[17] (25 × 1.8 Gy), and 3.2 % versus 2.4 % for the Upp-
sala Trial [20] and S-model [17] using 5 × 5 Gy.
Discussion
Similar to static multi-field intensity-modulated RT
(IMRT) use of VMAT results in superior target coverage
and OAR sparing than 3DCRT, reducing treatment-
induced toxicity, and has the potential to increase tumor
control in rectal cancer [21, 22]. However, larger vol-
umes of normal tissues are exposed to low dose ionizing
radiation using VMAT due to its continuous delivery
while the arc is rotating around the patient [23, 24]. In
this study, it was postulated that SCR differs using
VMAT while delivering a larger low dose bath to the
pelvis and more MU than with a three- or four-field
3DCRT box technique. There are several reasons that
could explain why we did not find a difference in SCR
comparing the two techniques. First, beam on time is
often longer with VMAT, thus increasing dynamic multi-
leaf collimator interleaf leakage as well as collimator
scatter, known to increase SCR [23, 25–27]; conversely,
use of hard or dynamic wedges with 3DCRT increases
beam on time and MU, neutralizing the advantage of
Fig. 2 LAR for each patient with 5 × 5 Gy, R = 1
Fig. 3 LAR with a variable age at exposure and attained age of 90 years for RT 25 × 1.8 Gy
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3DCRT with respect to shorter beam on time. Secondly,
dose coverage of a horseshoe-shaped PTV is more con-
formal with VMAT resulting in a smaller high dose vol-
ume. As a consequence, adjacent OAR are less exposed
to higher doses [28]. As is known from other studies,
SCR is highest in tissues or organs that are closely lo-
cated to or at the margins of the PTV [29, 30]; hence, a
smaller PTV potentially results in a decrease of SCR.
This fact may even compensate for the larger low dose
bath to the pelvis with VMAT otherwise responsible for
higher SCR [23, 31]. Thirdly, in our study MU count
was higher with VMAT compared to 3DCRT (Table 1).
As the treated volume and thus scatter dose was smaller,
higher number of MU with VMAT did not translate
Fig. 4 LAR with a variable age at exposure and attained age of 90 years for 5 × 5 Gy
Fig. 5 LAR for the patients treated with 30 × 2 Gy and 5 × 5 Gy (Uppsala Trial) [4, 20] as well as 25 × 1.8 Gy and 5 × 5y (S-model) [17] over
20 years (age 69 – 89) and no RT
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automatically into higher SCR. The fact that with a
highly conformal RT technique such as VMAT SCR can
be reduced is noted by the work of Rehman et al. report-
ing on lowest SCR with VMAT in spine radiotherapy
compared to 3DCRT and IMRT [28].
Most second cancers occur in organs adjacent to or
near the target volume [25, 29, 30]. Our study could
confirm this observation as higher LAR was found for
organs close to the PTV including colon, sigmoid, anus
and bladder irrespective of RT technique or fraction-
ation scheme (Tables 2 and 3). Comparing the RT
techniques used in this study, organ-specific LAR was
significantly lower using 3DCRT than VMAT. This is in
contrast to the studies by Rehman et al. and Mok et al.,
both reporting on lower doses to OAR close to the PTV
using either 6 MV VMAT or 6 MV IMRT [21, 28]. This
contradiction could be explained by the fact that despite
using 6 MV VMAT, irradiated volumes for rectal cancer
and for spine metastases are very different in size [28]
neutralizing the advantage of a highly conformal treat-
ment technique for the PTV with larger field sizes and
adding a larger low dose bath to organs around the
target volume with VMAT compared to 3DCRT [23]. It
should also be noted that when using 3DCRT to treat
rectal cancer, beam energy used is usually larger than 10
MV, and as a consequence production of secondary
neutrons occurs, contributing to increased SCR [25, 32].
Second malignancies after fractionated RT are of
increasing concern and influenced by cellular repopu-
lation during and shortly after treatment [33]. The
influence of fraction size on cellular repopulation fa-
voring second cancer induction is only partly under-
stood. Sachs et al. postulate in their stochastic
initiation/inactivation/proliferation (IIP) model that
fractionated higher dose RT leads to a growth advan-
tage for pre-malignant cells and therefore explains the
increase of the year-specific excess relative SCR inci-
dence for a specific organ. Taking into account the
weekend treatment gaps this effect is adversely related
to SCR, as repopulation during weekends tends to
increase the number of pre-malignant cells [33]. These
conclusions would favor hypofractionated RT regimens
in reducing SCR, as seen in our study. Manem et al.
showed in their work modeling tumor control prob-
ability and tumor recurrence time on the basis of the
linear quadratic model and SCR on the basis of the IIP
model [11] that with hypofractionation, SCR was re-
duced by 22 % compared to a conventional (2Gy) frac-
tionation schedule [34]. Schneider et al. also reported
that SCR decreases linearly by around 10–15 % per
1 Gy for both carcinoma and sarcoma induction with
increasing fractionation dose, and using conventional
rather than stereotactic RT, where this effect has not
been detected [35]. However, these findings, including our
own data based on the S-model [17], are in contradiction
to the epidemiological data by Birgisson et al. [4] showing
a trend towards a higher SCR using hypofractionation
(Fig. 5). One explanation could be that in the models used
so far, results were based on other histologies than seen in
rectal cancer and the effect of different fractionation is un-
known. Edmondson et al. demonstrated in their mouse
model that tumor induction using either a conventional
or single fractionation regimen was dependent on tumor
histology and hence genetic susceptibility, and in particu-
lar non-sarcomatous second cancer were seen more fre-
quently after exposure to RT in fractions of 2 Gy per day
[36]. Our group was able to show that sterilization of a
large number of cells at higher doses could lead to inflam-
mation or proliferative stress and initiate carcinogenesis.
This might explain why the models discussed so far incor-
rectly assume a decrease of SCR through hypofractiona-
tion. In particular, at doses > 20 Gy cancer induction could
be systematically underestimated in the current muta-
tional models, as tissue injury due to high doses of radi-
ation may be due to enhanced cell proliferation escaping
senescence and apoptosis [37]. However, the impact of
SCR on accelerated carcinogenesis after RT at different
dose levels remains an area for future research.
Compared to the detected increase in SCR of 2 %
for either technique, RT-induced cancer risk remains
low compared to spontaneous cancer induction for
the older patient population included in this study
(Fig. 3 and 4). Therefore, the question remains how
relevant is the detected increase for treatment deci-
sion making and does it potentially harm cancer
survivors. Tubiana stated that the incidence of second
primary malignancies had long been underestimated
due to the short life expectancy of most cancer
patients. However, with improvement of long-term
survival due to better treatment results, second
primary malignancies became relevant as the delay
between RT and second cancer may be as long as 10
years or more. Other factors influencing SCR include
type of tissue or organ, age of patient at treatment,
hereditary factors, but also RT volume and dose [1].
These findings have been confirmed by Hodgson et
al. in young female Hodgkin lymphoma survivors,
where treatment field size and dose substantially in-
fluenced SCR for consecutive breast and lung cancer
11-fold and 3.6-fold, respectively [38]. This is in con-
trast to the SCR found in this work, indicating that
in an older patient population second primary malig-
nancies for rectal cancer after RT occurred relatively
infrequently compared to spontaneously occurring
malignancies [5, 6].
A limitation of our study was that the results were
based on a mutational model and uncertainties were
involved in modeling the underlying biology of
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radiation-induced cancer. As very little is known about
the shape of the dose-response relationship for radiation-
induced cancer in the RT dose range currently applied,
our approach could be used to investigate at least quanti-
tatively fractionation dependence of second cancer induc-
tion. It should also be noted that in addition to the
limitations mentioned, the S-model [17] is a carcinogen-
esis model without acceleration and therefore time-related
effects independent of RT dose, such as the delayed start
of repopulation, were neglected [30]. Finally, the small
number of patients used for the present analysis consti-
tutes another limitation of the study.
Conclusion
In conclusion, this study showed no statistically signifi-
cant difference in SCR using either VMAT or 3DCRT.
Organ-specific LAR to develop a treatment-related sec-
ond cancer was higher with VMAT compared to 3DCRT
and highest for organs at risk neighbouring the PTV.
Compared to spontaneous cancer induction, radiation-
induced cancer risk was low. For both techniques, SCR
was approximately 2 % for the typical age (69 years) at
exposure. However, SCR could increase by 10 % for a
patient at 30 years of age, and SCR increased exponen-
tially with decreasing age at exposure to RT.
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